Boston-based drugmaker Vertex, which specializes in rare disorders like cystic fibrosis, doesn’t always attract Big Pharma–level attention. But the firm is on a serious growth trajectory, slated for double-digit expansion in the coming years, per analysts. And the company is branching out into new, brand-name science it hopes can add to its $43 billion market value, including a recent $950 million deal to acquire Semma Therapeutics—a startup that aims to use stem cells to cure Type 1 diabetes.
Subscribe to Fortune’s Brainstorm Health Daily newsletter, where we monitor advances in healthcare and biopharma.
|Revenues ($M) (Past 12 Months)||$3,454|
|Profits ($M) (Past 12 Months)||$2,215|
|Market Value as of Oct. 9, 2019 ($M)||$43,370|